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(ART) to account for daily variations in bladder filling. Prior 
to each fraction, a conebeam CT (CBCT) is acquired and 
registered to the planning CT using a Chamfer algorithm 
(Elekta XVI 4.5). A dedicated RTT chooses the best fitting 
plan from a library of five plans. When none of the five plans 
fit the bladder volume, fine-tuning of the bony anatomy 
registration is performed (tweak), in order to optimize target 
coverage.  
A tweak introduces an inter observer error and is a 
challenging time consuming part of the online CBCT 
registration workflow. We hypothesized that the rectum 
volume had a large influence on fine-tuning. The aim of this 
study was to investigate whether a significant correlation 
exists between rectum volume and performed tweak. 
 
Material and Methods: Prior to treatment, the tumor was 
marked during cystoscopy with lipiodol or hydrogel. Two 
planning CTs were acquired: full bladder 100%; empty 
bladder 0%. A structure-based algorithm was used to create 
five different target volumes: 0%, 33%, 67%, 100%, and 133%, 
to create five different VMAT plans. The bladder and lymph 
nodes were treated to 40 Gy, the tumor up to 55 Gy, in 20 
fractions using a simultaneously integrated boost. If none of 
the plans resulted in a good coverage of the bladder volume, 
the dedicated RTT had three options. The first two options 
were to instruct the patient to drink more and/or defecate: a 
100% bladder filling is preferred. The third option was to 
perform a tweak.  
A tweak should not exceed the PTV margins: 7 mm L-R (X), 8 
mm C-C (Y) and A-P (Z) and is restricted by adequate 
coverage of the high dose area, visible through the lipiodol or 
hydrogel. This area is considered clinically more important 
compared to the elective lymph nodes. 
189 CBCTs from 10 patients were analyzed. Bladder and 
rectum volumes from both CT and CBCT were recorded. The 
differences in rectum volume between CT and each CBCT 
were calculated, as well as the mean rectum volume 
(compared to the planning CT) and the vector length of the 
tweak (see figure 1). The correlation (R²) between the 
rectum volume and the tweak vector was calculated. 
 
 
 
Results: For fractions without a tweak the mean relative 
rectum volume was 99% compared to 79% for fractions in 
which a tweak was performed. The number of times each 
plan was chosen and the times a tweak was performed are 
shown in Table 1. 
 
 
 
Conclusion: A significant correlation was found between the 
vector length of the tweak and rectum volume difference 
between full bladder CT and CBCT. Also tweaking was 
necessary less often when the rectum volume remained 
stable. Further research is necessary to identify a range of 
rectum volumes that will probably remain stable during the 
course of treatment. 
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Purpose or Objective: The traditional paradigm for inverse 
planning does not always deliver a Pareto-optimal dose 
distribution. In addition, trade-offs between different organs 
at risk are often necessary. In a clinical setting centered on 
shared decision making (SDM) between patients and their 
physicians, we suggest that individual preferences could be 
incorporated into plan selection based on a family of optimal 
plans. We present interim results from an efficient workflow 
for plan generation with trade-off selection, based on multi-
criteria optimization (MCO). 
 
Material and Methods: In this pilot study, dose plans were 
retrospectively generated for four representative anal cancer 
patients. All were treated with intensity-modulated 
radiotherapy with a standard regimen (60.2 Gy simultaneous-
integrated tumor boost with 50.4 Gy to elective nodes, in 28 
fractions, high dose regimen) and physician-defined organ-
sparing priorities. In the first alternative plan generation, we 
optimized for minimum acceptable target volume coverage 
and same organ-sparing priorities, but assumed that the 
patient voluntarily foregoes the last three fractions of the 
standard regimen (tumor and nodal dose lowered by 6.45 Gy 
and 5.4 Gy, respectively, low dose regimen). Resulting 
changes in 2-year local tumor control probability were 
estimated using a model by Muirhead et al (Radiother Oncol 
2015;116: 192–196). In the second round of alternative plan 
generation, we used MCO to search the phase space of 
optimal plans at the shorter regimen that would maximize 
sparing of the bowel at the expense of the bladder (bowel 
sparing regimen), and vice versa (bladder sparing regimen). 
In this way, we simulated the maximum span of dose 
distributions available for individualized patient preferences 
in regards to toxicity avoidance. 
 
Results: Figure 1 demonstrates dose distributions for a single 
patient for the high dose, low dose, bowel sparing, and 
bladder sparing regimen. Dose metrics for bladder and bowel 
are shown in Table 1. All dose plans had clinically acceptable 
target coverage, and were deemed satisfactory by a senior 
oncologist. Considerable reduction of dose to the bowel was 
possible, not only by reduction in prescription dose 
(ΔV45Gy=289 ccm) but also further by prioritization of bowel 
in the plan optimization (ΔV45Gy=308 ccm). This resulted in 
bladder dose metrics no better than those for the high dose 
regimen. The reverse was seen for bladder sparing plans. 
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Overall, the possibility of sparing the bowel at the cost of 
extra dose to the bladder and vice versa was demonstrated. 
The estimated change in primary tumor control for high 
versus low dose regimen was less than 1% for early stage 
tumors and approximately 5% for late stage tumors. 
 
 
 
 
 
Conclusion: There is room in the optimization space for 
incorporation of patient outcome and toxicity preferences. 
This opens for SDM for anal cancer patients. The study is to 
be expanded, with results for a total of 22 patients to be 
presented at ESTRO 2016. 
 
Poster Viewing : 10: Physics: Functional Imaging II  
 
 
PV-0473  
Diagnostic and predictive values of quantitative analysis on 
T2-w and ADC map MRI in prostate cancer 
K. Gnep
1Centre Eugène Marquis, Radiotherapy, Rennes, France 
1, A. Fargeas2, R.E. Gutiérrez-Carvajal2, F. 
Commandeur2, R. Mathieu3, J.D. Ospina2, G. Jimenez2, T. 
Rohou4, O. Acosta2, R. De Crevoisier1 
2Inserm U1099- University of Rennes 1, LTSI, Rennes, France 
3Centre Hospitalo-Universitaire Pontchaillou, Urology, 
Rennes, France 
4Centre Eugène Marquis, Radiology, Rennes, France 
 
Purpose or Objective: To explore the ability of quantitative 
prostate T2-weighted (T2-w) and apparent diffusion 
coefficient maps (ADC) MRI using Haralick texture features: i) 
to differentiate prostate cancer (PC) from healthy tissues; ii) 
to be correlated with Gleason score; iii) to predict 
biochemical recurrence after external beam radiotherapy 
(RT) for prostate cancer. 
 
Material and Methods: Tumor and prostate zones were 
segmented on co-registered T2-w and ADC on two pre-
treatment 3.0T MRI from 83 patients with a median age 67 
years (range 50-82 years) and a median pre-treatment PSA of 
9.8 ng/ml (range 3.4-48.0 ng/ml). 9 (11%) tumors were 
localized in the transitional zone (TZ) and 74 (89%) in the 
peripheral zone (PZ). Tumors were clinically staged as 
follows: 13% of T1, 46% of T2 and 41% of T3. Gleason scores 
were as follows: 6 (27%), 7 (51%), 8 (20%) and 9 (2%). They 
were 2% of low-risk, 33% of intermediate-risk and 65% of 
high-risk tumors according to D’Amico risk group 
classification. Almost all patients received standard 
treatment consisting in IMRT (100%) with IGRT (94%) 
associated with hormonal therapy in 53% of the patients. 
After a median follow-up of 47 months (range 19-65 months), 
11 patients had biochemical recurrence. A total of 114 grey-
leveled features (first order, gradient-based and second 
order Haralick texture characteristics) and 4 geometrical 
features (maximal tumor diameter, maximal tumor 
perimeter, maximal tumor area and tumor volume) were 
extracted on normalized T2-w and ADC and were analyzed. 
Statistical analyses were performed using Wilcoxon signed-
rank test, Spearman’s correlation coefficient, Harrell’s C-
index, Kaplan-Meier curves and univariate Cox regression 
analysis. 
 
Results: i) 56 out of 57 T2-w and 46 out of 57 ADC grey-
leveled features were significantly different between tumor 
and prostate tissues in the PZ and 25 out of 57 T2-w and 37 
out of 57 ADC features in the TZ (p<0.05). ii) 5 T2-w features 
and 4 ADC features were significantly correlated with 
Gleason score, all were Haralick texture features. iii) T2-w 
features that significantly predicted (p<0.05) biochemical 
recurrence were: maximal tumor 
diameter/perimeter/area/volume, Kirsch gradient operator, 
normalized mean and standard deviation of signal intensity 
and 8 Haralick texture features (Difference Variance, 
Contrast, Inverse Difference Moment, Difference Entropy, 
Information Measure of Correlation, Sum Average, Sum 
Variance and Sum of Squares). Only normalized mean value 
on ADC was significantly predictive of biochemical 
recurrence. 
 
Conclusion: Quantitative analysis using Haralick texture 
characteristics on T2-w MRI are good features: i) to 
differentiate prostate cancer from healthy tissues, ii) for 
Gleason score assessment and iii) to predict biochemical 
recurrence after RT. Geometrical characteristics extracted 
from T2-w are also good predictors of biochemical recurrence 
after RT. 
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Purpose or Objective: Tumour hypoxia is associated with 
poor response to radiotherapy. Comprehensive hypoxia 
assessment through [18F]-fluoromisonidazole (FMISO) PET 
imaging requires quantitative techniques, such as dynamic 
acquisition. However, dynamic FMISO PET protocols might be 
simplified by using DCE-MRI imaging in addition to static 
FMISO-PET. The aim of this work was to compare FMISO and 
DCE-MRI kinetic parameters by means of correlation analysis. 
 
Material and Methods: This study was done on N=6 head and 
neck cancer patients, who were imaged dynamically with 
FMISO-PET and DCE-MRI on the same day. Images were 
registered and analyzed for kinetics on a voxel basis. FMISO-
